Folic Acid and Leucovorin Have Potential to Prevent SARS-CoV-2-Virus Internalization by Interacting with S-Glycoprotein/Neuropilin-1 Receptor Complex

The interaction of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain with the host-cell ACE2 receptor is a well-known step in virus infection. Neuropilin-1 (NRP-1) is another host factor involved in virus internalization. The interaction between S-glycoprotein and NRP-1 has been identifi...

Full description

Saved in:
Bibliographic Details
Published inMolecules (Basel, Switzerland) Vol. 28; no. 5; p. 2294
Main Authors Škrbić, Ranko, Travar, Maja, Stojiljković, Miloš P., Djuric, Dragan M., Suručić, Relja
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.03.2023
MDPI
Subjects
Amino acids
Angiogenesis
Antiretroviral drugs
Antiviral agents
Blood vessels
Cell receptors
Coronaviruses
COVID-19
COVID-19 Drug Treatment
Flexibility
Folic acid
Folic Acid - metabolism
Glycoproteins
Glycoproteins - metabolism
Health aspects
Humans
in silico
in vitro
Infections
Leucovorin
Ligands
Molecular Docking Simulation
Nervous system
neuropilin-1
Neuropilin-1 - metabolism
Permeability
Pharmaceutical research
Protein Binding
Proteins
RNA polymerase
SARS-CoV-2 - metabolism
Severe acute respiratory syndrome coronavirus 2
Simulation
Testing
Vascular endothelial growth factor
Viral infections
Virus Internalization
Vitamin B
Bosnia and Herzegovina
COVID-19
SARS-CoV-2
in vitro
neuropilin-1
in silico
folic acid
leucovorin
Online AccessGet full text
ISSN1420-3049
1420-3049
DOI10.3390/molecules28052294

Cover

Abstract The interaction of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain with the host-cell ACE2 receptor is a well-known step in virus infection. Neuropilin-1 (NRP-1) is another host factor involved in virus internalization. The interaction between S-glycoprotein and NRP-1 has been identified as a potential COVID-19 treatment target. Herein, the effectiveness of folic acid and leucovorin in preventing contact between S-glycoprotein and NRP-1 receptors was investigated using in silico studies and then confirmed in vitro. The results of a molecular docking study showed that leucovorin and folic acid had lower binding energies than EG01377, a well-known NRP-1 inhibitor, and lopinavir. Two hydrogen bonds with Asp 320 and Asn 300 residues stabilized the leucovorin, while interactions with Gly 318, Thr 349, and Tyr 353 residues stabilized the folic acid. The molecular dynamic simulation revealed that the folic acid and leucovorin created very stable complexes with the NRP-1. The in vitro studies showed that the leucovorin was the most active inhibitor of the S1-glycoprotein/NRP-1 complex formation, with an IC75 value of 185.95 µg/mL. The results of this study suggest that folic acid and leucovorin could be considered as potential inhibitors of the S-glycoprotein/NRP-1 complex and, thus, could prevent the SARS-CoV-2 virus’ entry into host cells.
AbstractList The interaction of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain with the host-cell ACE2 receptor is a well-known step in virus infection. Neuropilin-1 (NRP-1) is another host factor involved in virus internalization. The interaction between S-glycoprotein and NRP-1 has been identified as a potential COVID-19 treatment target. Herein, the effectiveness of folic acid and leucovorin in preventing contact between S-glycoprotein and NRP-1 receptors was investigated using in silico studies and then confirmed in vitro. The results of a molecular docking study showed that leucovorin and folic acid had lower binding energies than EG01377, a well-known NRP-1 inhibitor, and lopinavir. Two hydrogen bonds with Asp 320 and Asn 300 residues stabilized the leucovorin, while interactions with Gly 318, Thr 349, and Tyr 353 residues stabilized the folic acid. The molecular dynamic simulation revealed that the folic acid and leucovorin created very stable complexes with the NRP-1. The in vitro studies showed that the leucovorin was the most active inhibitor of the S1-glycoprotein/NRP-1 complex formation, with an IC75 value of 185.95 µg/mL. The results of this study suggest that folic acid and leucovorin could be considered as potential inhibitors of the S-glycoprotein/NRP-1 complex and, thus, could prevent the SARS-CoV-2 virus' entry into host cells.The interaction of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain with the host-cell ACE2 receptor is a well-known step in virus infection. Neuropilin-1 (NRP-1) is another host factor involved in virus internalization. The interaction between S-glycoprotein and NRP-1 has been identified as a potential COVID-19 treatment target. Herein, the effectiveness of folic acid and leucovorin in preventing contact between S-glycoprotein and NRP-1 receptors was investigated using in silico studies and then confirmed in vitro. The results of a molecular docking study showed that leucovorin and folic acid had lower binding energies than EG01377, a well-known NRP-1 inhibitor, and lopinavir. Two hydrogen bonds with Asp 320 and Asn 300 residues stabilized the leucovorin, while interactions with Gly 318, Thr 349, and Tyr 353 residues stabilized the folic acid. The molecular dynamic simulation revealed that the folic acid and leucovorin created very stable complexes with the NRP-1. The in vitro studies showed that the leucovorin was the most active inhibitor of the S1-glycoprotein/NRP-1 complex formation, with an IC75 value of 185.95 µg/mL. The results of this study suggest that folic acid and leucovorin could be considered as potential inhibitors of the S-glycoprotein/NRP-1 complex and, thus, could prevent the SARS-CoV-2 virus' entry into host cells.
The interaction of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain with the host-cell ACE2 receptor is a well-known step in virus infection. Neuropilin-1 (NRP-1) is another host factor involved in virus internalization. The interaction between S-glycoprotein and NRP-1 has been identified as a potential COVID-19 treatment target. Herein, the effectiveness of folic acid and leucovorin in preventing contact between S-glycoprotein and NRP-1 receptors was investigated using in silico studies and then confirmed in vitro. The results of a molecular docking study showed that leucovorin and folic acid had lower binding energies than EG01377, a well-known NRP-1 inhibitor, and lopinavir. Two hydrogen bonds with Asp 320 and Asn 300 residues stabilized the leucovorin, while interactions with Gly 318, Thr 349, and Tyr 353 residues stabilized the folic acid. The molecular dynamic simulation revealed that the folic acid and leucovorin created very stable complexes with the NRP-1. The in vitro studies showed that the leucovorin was the most active inhibitor of the S1-glycoprotein/NRP-1 complex formation, with an IC75 value of 185.95 µg/mL. The results of this study suggest that folic acid and leucovorin could be considered as potential inhibitors of the S-glycoprotein/NRP-1 complex and, thus, could prevent the SARS-CoV-2 virus’ entry into host cells.
The interaction of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain with the host-cell ACE2 receptor is a well-known step in virus infection. Neuropilin-1 (NRP-1) is another host factor involved in virus internalization. The interaction between S-glycoprotein and NRP-1 has been identified as a potential COVID-19 treatment target. Herein, the effectiveness of folic acid and leucovorin in preventing contact between S-glycoprotein and NRP-1 receptors was investigated using in silico studies and then confirmed in vitro. The results of a molecular docking study showed that leucovorin and folic acid had lower binding energies than EG01377, a well-known NRP-1 inhibitor, and lopinavir. Two hydrogen bonds with Asp 320 and Asn 300 residues stabilized the leucovorin, while interactions with Gly 318, Thr 349, and Tyr 353 residues stabilized the folic acid. The molecular dynamic simulation revealed that the folic acid and leucovorin created very stable complexes with the NRP-1. The in vitro studies showed that the leucovorin was the most active inhibitor of the S1-glycoprotein/NRP-1 complex formation, with an IC 75 value of 185.95 µg/mL. The results of this study suggest that folic acid and leucovorin could be considered as potential inhibitors of the S-glycoprotein/NRP-1 complex and, thus, could prevent the SARS-CoV-2 virus’ entry into host cells.
The interaction of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain with the host-cell ACE2 receptor is a well-known step in virus infection. Neuropilin-1 (NRP-1) is another host factor involved in virus internalization. The interaction between S-glycoprotein and NRP-1 has been identified as a potential COVID-19 treatment target. Herein, the effectiveness of folic acid and leucovorin in preventing contact between S-glycoprotein and NRP-1 receptors was investigated using in silico studies and then confirmed in vitro. The results of a molecular docking study showed that leucovorin and folic acid had lower binding energies than EG01377, a well-known NRP-1 inhibitor, and lopinavir. Two hydrogen bonds with Asp 320 and Asn 300 residues stabilized the leucovorin, while interactions with Gly 318, Thr 349, and Tyr 353 residues stabilized the folic acid. The molecular dynamic simulation revealed that the folic acid and leucovorin created very stable complexes with the NRP-1. The in vitro studies showed that the leucovorin was the most active inhibitor of the S1-glycoprotein/NRP-1 complex formation, with an IC[sub.75] value of 185.95 µg/mL. The results of this study suggest that folic acid and leucovorin could be considered as potential inhibitors of the S-glycoprotein/NRP-1 complex and, thus, could prevent the SARS-CoV-2 virus’ entry into host cells.
The interaction of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain with the host-cell ACE2 receptor is a well-known step in virus infection. Neuropilin-1 (NRP-1) is another host factor involved in virus internalization. The interaction between S-glycoprotein and NRP-1 has been identified as a potential COVID-19 treatment target. Herein, the effectiveness of folic acid and leucovorin in preventing contact between S-glycoprotein and NRP-1 receptors was investigated using in silico studies and then confirmed in vitro. The results of a molecular docking study showed that leucovorin and folic acid had lower binding energies than EG01377, a well-known NRP-1 inhibitor, and lopinavir. Two hydrogen bonds with Asp 320 and Asn 300 residues stabilized the leucovorin, while interactions with Gly 318, Thr 349, and Tyr 353 residues stabilized the folic acid. The molecular dynamic simulation revealed that the folic acid and leucovorin created very stable complexes with the NRP-1. The in vitro studies showed that the leucovorin was the most active inhibitor of the S1-glycoprotein/NRP-1 complex formation, with an IC value of 185.95 µg/mL. The results of this study suggest that folic acid and leucovorin could be considered as potential inhibitors of the S-glycoprotein/NRP-1 complex and, thus, could prevent the SARS-CoV-2 virus' entry into host cells.
Audience Academic
Author Suručić, Relja
Stojiljković, Miloš P.
Škrbić, Ranko
Djuric, Dragan M.
Travar, Maja
AuthorAffiliation 2 Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, The Republic of Srpska, Bosnia and Herzegovina
4 Institute of Medical Physiology “Richard Burian”, Faculty of Medicine, University of Belgrade, Višegradska 26/2, 11000 Belgrade, Serbia
5 Department of Pharmacognosy, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, The Republic of Srpska, Bosnia and Herzegovina
3 Department of Microbiology, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, The Republic of Srpska, Bosnia and Herzegovina
1 Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, The Republic of Srpska, Bosnia and Herzegovina
AuthorAffiliation_xml – name: 2 Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, The Republic of Srpska, Bosnia and Herzegovina
– name: 5 Department of Pharmacognosy, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, The Republic of Srpska, Bosnia and Herzegovina
– name: 3 Department of Microbiology, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, The Republic of Srpska, Bosnia and Herzegovina
– name: 4 Institute of Medical Physiology “Richard Burian”, Faculty of Medicine, University of Belgrade, Višegradska 26/2, 11000 Belgrade, Serbia
– name: 1 Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, The Republic of Srpska, Bosnia and Herzegovina
Author_xml – sequence: 1
  givenname: Ranko
  orcidid: 0000-0002-6643-1781
  surname: Škrbić
  fullname: Škrbić, Ranko
– sequence: 2
  givenname: Maja
  surname: Travar
  fullname: Travar, Maja
– sequence: 3
  givenname: Miloš P.
  orcidid: 0000-0001-9431-0736
  surname: Stojiljković
  fullname: Stojiljković, Miloš P.
– sequence: 4
  givenname: Dragan M.
  orcidid: 0000-0003-2196-9438
  surname: Djuric
  fullname: Djuric, Dragan M.
– sequence: 5
  givenname: Relja
  surname: Suručić
  fullname: Suručić, Relja
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36903540$$D View this record in MEDLINE/PubMed
BookMark eNp9kstu1DAUhiNURC_wAGyQJTZs0voaJys0GtGLNIKqA91GjnMy9cixg5MMDO_B--KZKaVTEPLC9sn3__Zx_uPkwHkHSfKa4FPGCnzWegt6tNDTHAtKC_4sOSKc4pRhXhw8Wh8mx32_xJgSTsSL5JBlBWaC46Pk57m3RqOJNjVSrkYzGLVf-WAculQrQNd-ADcYZdHg0XWAVdyh-eRmnk79bUrTWxPGHl25AYJT1vxQg_EOVetdSenBuAX6ZoY7NE8v7Fr7LkRH484-whh8Z6xxKUE3oKEbfEBT33YWvr9MnjfK9vDqfj5Jvpx_-Dy9TGefLq6mk1mqRUaGVGZ5A7KqdJ3lkPNG1JxDJSHDBWGCSCp4jakmmRQ5L3BNi5rTuqIgcsyapmInydXOt_ZqWXbBtCqsS69MuS34sChVGIy2UBaMZnVOOSNScc2zgoiM5RKaImuI5iR6vd95dWPVQq3jQwVl90z3vzhzVy78qiQYY8E5iw7v7h2C_zpCP5St6TVYqxz4sS-pzGNnVEoc0bdP0KUfN39gSwlKWAzIH2qhYgfGNT4erDem5URyknOBuYzU6T-oOGpojY6Ja0ys7wnePO70ocXfqYoA2QE6-L4P0DwgBJeb5JZ_JTdq5BONNsM2TfE2xv5H-Qv-r_Ry
CitedBy_id crossref_primary_10_4103_JAPTR_JAPTR_242_23
crossref_primary_10_3892_etm_2023_12340
crossref_primary_10_3390_microorganisms11122953
crossref_primary_10_3390_biom14010043
crossref_primary_10_1002_cbdv_202301227
crossref_primary_10_1016_j_biopha_2023_115558
crossref_primary_10_3390_nu15153451
Cites_doi 10.1021/acs.jmedchem.8b00210
10.3389/fpubh.2020.00476
10.1016/j.bpj.2021.05.026
10.1038/sj.emboj.7601906
10.1007/s10456-012-9289-6
10.1056/NEJMoa2023184
10.1080/13880209.2022.2063341
10.1038/s41598-018-34859-w
10.1007/978-1-61779-465-0_25
10.1007/s00894-022-05138-3
10.1016/j.bmc.2021.116040
10.1126/science.abd3072
10.2174/1573409916666200422075440
10.1080/07391102.2020.1805019
10.1186/s11658-022-00311-1
10.3390/molecules27165174
10.1097/j.pain.0000000000002097
10.1007/s00277-002-0560-6
10.1093/eurpub/ckab165.243
10.1007/s13337-021-00751-x
10.1093/nutrit/nuaa063
10.1038/s41580-021-00418-x
10.1021/acschemneuro.0c00294
10.1111/micc.12124
10.1126/science.abb2507
10.1111/sji.12960
10.1016/j.molcel.2020.04.022
10.15252/embj.2020105114
10.1042/BJ20071639
10.3390/nu13030812
10.3390/ph15020165
10.1126/science.abd2985
10.1093/ajcn/nqx076
10.1038/s41598-017-00839-9
10.1016/j.csbj.2021.03.025
10.1007/s11095-009-0035-8
10.1038/s41598-019-51050-x
10.1016/j.yebeh.2020.107569
10.1007/s42485-021-00074-x
10.1007/s13337-020-00643-6
10.1101/2020.09.22.308783
10.3389/fphar.2020.01062
10.3390/pathogens9030231
10.26434/chemrxiv.12034980
10.1016/j.str.2016.08.017
10.1074/jbc.M111.331140
ContentType Journal Article
Copyright COPYRIGHT 2023 MDPI AG
2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2023 by the authors. 2023
Copyright_xml – notice: COPYRIGHT 2023 MDPI AG
– notice: 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2023 by the authors. 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
COVID
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.3390/molecules28052294
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
Coronavirus Research Database
ProQuest Central
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journal Collection
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

Publicly Available Content Database


CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
EISSN 1420-3049
ExternalDocumentID oai_doaj_org_article_9326d824317a4c469156387ef96f1c41
PMC10005443
A741845047
36903540
10_3390_molecules28052294
Genre Journal Article
GeographicLocations Bosnia and Herzegovina
GeographicLocations_xml – name: Bosnia and Herzegovina
GroupedDBID ---
0R~
123
2WC
53G
5VS
7X7
88E
8FE
8FG
8FH
8FI
8FJ
A8Z
AADQD
AAFWJ
AAHBH
AAYXX
ABDBF
ABUWG
ACGFO
ACIWK
ACPRK
ACUHS
AEGXH
AENEX
AFKRA
AFPKN
AFRAH
AFZYC
AIAGR
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BENPR
BPHCQ
BVXVI
CCPQU
CITATION
CS3
D1I
DIK
DU5
E3Z
EBD
EMOBN
ESX
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
HZ~
I09
IAO
IHR
ITC
KQ8
LK8
M1P
MODMG
O-U
O9-
OK1
P2P
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RPM
SV3
TR2
TUS
UKHRP
~8M
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
3V.
7XB
8FK
AZQEC
COVID
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c561t-768fe7bbcd68e84f5d44eb7e60913517254d02c16758490d29d42db2e5803ffb3
IEDL.DBID DOA
ISSN 1420-3049
IngestDate Wed Aug 27 01:32:05 EDT 2025
Thu Aug 21 18:37:45 EDT 2025
Fri Sep 05 03:52:30 EDT 2025
Fri Jul 25 09:31:26 EDT 2025
Tue Jun 17 22:04:39 EDT 2025
Tue Jun 10 21:07:31 EDT 2025
Mon Jul 21 06:00:48 EDT 2025
Tue Jul 01 01:21:56 EDT 2025
Thu Apr 24 23:05:29 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords COVID-19
SARS-CoV-2
in vitro
neuropilin-1
in silico
folic acid
leucovorin
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c561t-768fe7bbcd68e84f5d44eb7e60913517254d02c16758490d29d42db2e5803ffb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-2196-9438
0000-0002-6643-1781
0000-0001-9431-0736
OpenAccessLink https://doaj.org/article/9326d824317a4c469156387ef96f1c41
PMID 36903540
PQID 2785213339
PQPubID 2032355
ParticipantIDs doaj_primary_oai_doaj_org_article_9326d824317a4c469156387ef96f1c41
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10005443
proquest_miscellaneous_2786092770
proquest_journals_2785213339
gale_infotracmisc_A741845047
gale_infotracacademiconefile_A741845047
pubmed_primary_36903540
crossref_primary_10_3390_molecules28052294
crossref_citationtrail_10_3390_molecules28052294
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-03-01
PublicationDateYYYYMMDD 2023-03-01
PublicationDate_xml – month: 03
  year: 2023
  text: 2023-03-01
  day: 01
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Molecules (Basel, Switzerland)
PublicationTitleAlternate Molecules
PublicationYear 2023
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Yin (ref_14) 2020; 11
Choudhary (ref_17) 2021; 12
Wang (ref_32) 2017; 7
Vajda (ref_36) 2021; 114
Charoute (ref_37) 2022; 33
Remacha (ref_34) 2002; 81
Elzayat (ref_4) 2018; 8
Lukassen (ref_6) 2020; 39
(ref_40) 2021; 33
Krieger (ref_46) 2012; 819
ref_16
Daly (ref_8) 2020; 370
Wrapp (ref_5) 2020; 367
Jobe (ref_39) 2021; 19
Powell (ref_44) 2018; 61
Lin (ref_30) 2012; 15
Moutal (ref_15) 2022; 162
Appleton (ref_11) 2007; 26
Parker (ref_38) 2012; 287
Pacheco (ref_19) 2021; 93
Kumar (ref_42) 2021; 32
ref_25
Eskandari (ref_20) 2022; 28
Jackson (ref_1) 2022; 23
Hoffmann (ref_2) 2020; 78
Yelland (ref_12) 2016; 24
ref_23
Plein (ref_10) 2014; 21
Li (ref_13) 2021; 120
Chaari (ref_22) 2020; 8
Frankel (ref_9) 2008; 411
ref_3
Kim (ref_31) 2018; 107
(ref_24) 2020; 11
Ojha (ref_7) 2020; 370
Zalpoor (ref_18) 2022; 27
ref_28
ref_27
ref_26
Consortium (ref_45) 2021; 384
Pirouzpanah (ref_35) 2019; 9
Akhtar (ref_21) 2021; 79
Bechet (ref_33) 2010; 27
Chen (ref_29) 2022; 60
Serseg (ref_41) 2021; 17
Lokhande (ref_43) 2021; 39
References_xml – volume: 61
  start-page: 4135
  year: 2018
  ident: ref_44
  article-title: Small Molecule Neuropilin-1 Antagonists Combine Antiangiogenic and Antitumor Activity with Immune Modulation through Reduction of Transforming Growth Factor Beta (TGFbeta) Production in Regulatory T-Cells
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.8b00210
– volume: 8
  start-page: 476
  year: 2020
  ident: ref_22
  article-title: Importance of Dietary Changes During the Coronavirus Pandemic: How to Upgrade Your Immune Response
  publication-title: Front. Public Health
  doi: 10.3389/fpubh.2020.00476
– volume: 120
  start-page: 2828
  year: 2021
  ident: ref_13
  article-title: Neuropilin-1 assists SARS-CoV-2 infection by stimulating the separation of Spike protein S1 and S2
  publication-title: Biophys. J.
  doi: 10.1016/j.bpj.2021.05.026
– volume: 26
  start-page: 4902
  year: 2007
  ident: ref_11
  article-title: Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding
  publication-title: EMBO J.
  doi: 10.1038/sj.emboj.7601906
– volume: 15
  start-page: 671
  year: 2012
  ident: ref_30
  article-title: Folic acid inhibits endothelial cell proliferation through activating the cSrc/ERK 2/NF-kappaB/p53 pathway mediated by folic acid receptor
  publication-title: Angiogenesis
  doi: 10.1007/s10456-012-9289-6
– volume: 384
  start-page: 497
  year: 2021
  ident: ref_45
  article-title: Repurposed Antiviral Drugs for COVID-19-Interim WHO Solidarity Trial Results
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2023184
– volume: 60
  start-page: 862
  year: 2022
  ident: ref_29
  article-title: Folic acid: A potential inhibitor against SARS-CoV-2 nucleocapsid protein
  publication-title: Pharm. Biol.
  doi: 10.1080/13880209.2022.2063341
– volume: 8
  start-page: 16597
  year: 2018
  ident: ref_4
  article-title: Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-018-34859-w
– volume: 819
  start-page: 405
  year: 2012
  ident: ref_46
  article-title: Assignment of protonation states in proteins and ligands: Combining pKa prediction with hydrogen bonding network optimization
  publication-title: Methods Mol. Biol.
  doi: 10.1007/978-1-61779-465-0_25
– volume: 28
  start-page: 153
  year: 2022
  ident: ref_20
  article-title: Repurposing the natural compounds as potential therapeutic agents for COVID-19 based on the molecular docking study of the main protease and the receptor-binding domain of spike protein
  publication-title: J. Mol. Model.
  doi: 10.1007/s00894-022-05138-3
– volume: 33
  start-page: 116040
  year: 2021
  ident: ref_40
  article-title: Potential inhibitors interacting in Neuropilin-1 to develop an adjuvant drug against COVID-19, by molecular docking
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2021.116040
– volume: 370
  start-page: 861
  year: 2020
  ident: ref_8
  article-title: Neuropilin-1 is a host factor for SARS-CoV-2 infection
  publication-title: Science
  doi: 10.1126/science.abd3072
– volume: 17
  start-page: 469
  year: 2021
  ident: ref_41
  article-title: Hispidin and Lepidine E: Two Natural Compounds and Folic Acid as Potential Inhibitors of 2019-novel Coronavirus Main Protease (2019-nCoVM(pro)), Molecular Docking and SAR Study
  publication-title: Curr. Comput. Aided Drug Des.
  doi: 10.2174/1573409916666200422075440
– volume: 39
  start-page: 7294
  year: 2021
  ident: ref_43
  article-title: Molecular docking and simulation studies on SARS-CoV-2 M(pro) reveals Mitoxantrone, Leucovorin, Birinapant, and Dynasore as potent drugs against COVID-19
  publication-title: J. Biomol. Struct. Dyn.
  doi: 10.1080/07391102.2020.1805019
– volume: 27
  start-page: 10
  year: 2022
  ident: ref_18
  article-title: The roles of Eph receptors, neuropilin-1, P2X7, and CD147 in COVID-19-associated neurodegenerative diseases: Inflammasome and JaK inhibitors as potential promising therapies
  publication-title: Cell Mol. Biol. Lett.
  doi: 10.1186/s11658-022-00311-1
– ident: ref_27
  doi: 10.3390/molecules27165174
– volume: 162
  start-page: 243
  year: 2022
  ident: ref_15
  article-title: SARS-CoV-2 Spike protein co-opts VEGF-A/Neuropilin-1 receptor signaling to induce analgesia
  publication-title: Pain
  doi: 10.1097/j.pain.0000000000002097
– volume: 81
  start-page: 616
  year: 2002
  ident: ref_34
  article-title: Enhanced risk of thrombotic disease in patients with acquired vitamin B12 and/or folate deficiency: Role of hyperhomocysteinemia
  publication-title: Ann. Hematol.
  doi: 10.1007/s00277-002-0560-6
– ident: ref_23
  doi: 10.1093/eurpub/ckab165.243
– volume: 33
  start-page: 23
  year: 2022
  ident: ref_37
  article-title: Computational screening of potential drugs against COVID-19 disease: The Neuropilin-1 receptor as molecular target
  publication-title: Virusdisease
  doi: 10.1007/s13337-021-00751-x
– volume: 79
  start-page: 289
  year: 2021
  ident: ref_21
  article-title: Nutritional perspectives for the prevention and mitigation of COVID-19
  publication-title: Nutr. Rev.
  doi: 10.1093/nutrit/nuaa063
– volume: 23
  start-page: 3
  year: 2022
  ident: ref_1
  article-title: Mechanisms of SARS-CoV-2 entry into cells
  publication-title: Nat. Rev. Mol. Cell Biol.
  doi: 10.1038/s41580-021-00418-x
– volume: 11
  start-page: 1704
  year: 2020
  ident: ref_14
  article-title: Vascular endothelial growth factor (VEGF) as a vital target for brain inflammation during the COVID-19 outbreak
  publication-title: ACS Chem. Neurosci.
  doi: 10.1021/acschemneuro.0c00294
– volume: 21
  start-page: 315
  year: 2014
  ident: ref_10
  article-title: Neuropilin regulation of angiogenesis, arteriogenesis, and vascular permeability
  publication-title: Microcirculation
  doi: 10.1111/micc.12124
– volume: 367
  start-page: 1260
  year: 2020
  ident: ref_5
  article-title: Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
  publication-title: Science
  doi: 10.1126/science.abb2507
– volume: 93
  start-page: e12960
  year: 2021
  ident: ref_19
  article-title: The potential involvement of P2X7 receptor in COVID-19 pathogenesis: A new therapeutic target?
  publication-title: Scand. J. Immunol.
  doi: 10.1111/sji.12960
– volume: 78
  start-page: 779
  year: 2020
  ident: ref_2
  article-title: A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2020.04.022
– volume: 39
  start-page: e105114
  year: 2020
  ident: ref_6
  article-title: SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells
  publication-title: EMBO J.
  doi: 10.15252/embj.2020105114
– volume: 411
  start-page: 211
  year: 2008
  ident: ref_9
  article-title: Neuropilins: Structure, function and role in disease
  publication-title: Biochem. J.
  doi: 10.1042/BJ20071639
– ident: ref_25
  doi: 10.3390/nu13030812
– ident: ref_26
  doi: 10.3390/ph15020165
– volume: 370
  start-page: 856
  year: 2020
  ident: ref_7
  article-title: Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity
  publication-title: Science
  doi: 10.1126/science.abd2985
– volume: 107
  start-page: 139
  year: 2018
  ident: ref_31
  article-title: Folate and cancer: A tale of Dr. Jekyll and Mr. Hyde?
  publication-title: Am. J. Clin. Nutr.
  doi: 10.1093/ajcn/nqx076
– volume: 7
  start-page: 682
  year: 2017
  ident: ref_32
  article-title: Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-017-00839-9
– volume: 19
  start-page: 1889
  year: 2021
  ident: ref_39
  article-title: Neuropilins: C-end rule peptides and their association with nociception and COVID-19
  publication-title: Comput. Struct. Biotechnol. J.
  doi: 10.1016/j.csbj.2021.03.025
– volume: 27
  start-page: 468
  year: 2010
  ident: ref_33
  article-title: Neuropilin-1 targeting photosensitization-induced early stages of thrombosis via tissue factor release
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-009-0035-8
– volume: 9
  start-page: 14851
  year: 2019
  ident: ref_35
  article-title: The contribution of dietary and plasma folate and cobalamin to levels of angiopoietin-1, angiopoietin-2 and Tie-2 receptors depend on vascular endothelial growth factor status of primary breast cancer patients
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-019-51050-x
– volume: 114
  start-page: 107569
  year: 2021
  ident: ref_36
  article-title: Folic acid dose, valproate, and fetal malformations
  publication-title: Epilepsy Behav.
  doi: 10.1016/j.yebeh.2020.107569
– volume: 12
  start-page: 257
  year: 2021
  ident: ref_17
  article-title: Therapeutically effective covalent spike protein inhibitors in treatment of SARS-CoV-2
  publication-title: J. Proteins Proteom.
  doi: 10.1007/s42485-021-00074-x
– volume: 32
  start-page: 29
  year: 2021
  ident: ref_42
  article-title: In silico virtual screening-based study of nutraceuticals predicts the therapeutic potentials of folic acid and its derivatives against COVID-19
  publication-title: Virusdisease
  doi: 10.1007/s13337-020-00643-6
– ident: ref_16
  doi: 10.1101/2020.09.22.308783
– volume: 11
  start-page: 1062
  year: 2020
  ident: ref_24
  article-title: The Folate Concentration and/or Folic Acid Metabolites in Plasma as Factor for COVID-19 Infection
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2020.01062
– ident: ref_3
  doi: 10.3390/pathogens9030231
– ident: ref_28
  doi: 10.26434/chemrxiv.12034980
– volume: 24
  start-page: 2008
  year: 2016
  ident: ref_12
  article-title: Crystal Structure of the Neuropilin-1 MAM Domain: Completing the Neuropilin-1 Ectodomain Picture
  publication-title: Structure
  doi: 10.1016/j.str.2016.08.017
– volume: 287
  start-page: 11082
  year: 2012
  ident: ref_38
  article-title: Structural basis for selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M111.331140
SSID ssj0021415
Score 2.4189746
Snippet The interaction of the SARS-CoV-2 spike (S) glycoprotein receptor-binding domain with the host-cell ACE2 receptor is a well-known step in virus infection....
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 2294
SubjectTerms Amino acids
Angiogenesis
Antiretroviral drugs
Antiviral agents
Blood vessels
Cell receptors
Coronaviruses
COVID-19
COVID-19 Drug Treatment
Flexibility
Folic acid
Folic Acid - metabolism
Glycoproteins
Glycoproteins - metabolism
Health aspects
Humans
in silico
in vitro
Infections
Leucovorin
Ligands
Molecular Docking Simulation
Nervous system
neuropilin-1
Neuropilin-1 - metabolism
Permeability
Pharmaceutical research
Protein Binding
Proteins
RNA polymerase
SARS-CoV-2 - metabolism
Severe acute respiratory syndrome coronavirus 2
Simulation
Testing
Vascular endothelial growth factor
Viral infections
Virus Internalization
Vitamin B
SummonAdditionalLinks – databaseName: ProQuest Technology Collection
  dbid: 8FG
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96PuiL-G31lAiCIIRrk7RJnmRd3FtERFzvuLfSfPRcWNt1Pw7vD_H_dabNrlcO7rVJStOZZH4zmfyGkLei8iZkApTXOnBQlLJMy5CxKg2wstI6BW8Osy2-FtMT-fksP4sBt3VMq9ztid1G7VuHMfIjrjRYGiGE-bD8zbBqFJ6uxhIat8mdDCwN6rmeHO8drgysU3-SCcPSo199wdmw5sjjz40c2KKOsv_6xnzFMg2zJq-YockDcj_iRzrqBf6Q3ArNI3J3vCvb9pj8nSDTLx25uadV4-mXsHXtBabZ0Wl1Eei3doMJQvCOTUsjgROdjb7P2Lg9ZZydzlfbNY2BwkW8pUntZf8Ir0E05xSjt3TGjheXru2YHsC97mg-lnOArSyjgEbDEtx5ivvNIvx5Qk4mn36MpyzWXmAOENWGgRdSB2Wt84UOWta5lzJYFQrkEc0B9eTSp9xl6G9Ik3puvOTe8pDrVNS1FU_JQdM24TmhtVfCSeFA8EbCy3QQzvIiCGNNplWdkHQnhdJFYnKsj7EowUFBwZXXBJeQ9_shy56V46bOH1G0-45IqN09aFfnZVyfJcJYrznCqUo6WRjwa4VWoTZFnTmZJeQdKkaJyx4-zlXx9gJMEQm0yhGyAMk8lSohh4OeIH43bN6pVhm3i3X5X7kT8mbfjCMxBa4J7bbrAz-fK5Um5FmvifspicKkGMBLiB7o6GDOw5Zm_rMjE8861C7Fi5u_6yW5xwHe9dl3h-Rgs9qGVwDHNvZ1t-b-AZ5VNwg
  priority: 102
  providerName: ProQuest
Title Folic Acid and Leucovorin Have Potential to Prevent SARS-CoV-2-Virus Internalization by Interacting with S-Glycoprotein/Neuropilin-1 Receptor Complex
URI https://www.ncbi.nlm.nih.gov/pubmed/36903540
https://www.proquest.com/docview/2785213339
https://www.proquest.com/docview/2786092770
https://pubmed.ncbi.nlm.nih.gov/PMC10005443
https://doaj.org/article/9326d824317a4c469156387ef96f1c41
Volume 28
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1da9swFBVb97C9jH3PWxc0GAwGprIkW_JjGpqGMUpp1pI3Y324C2R2aJKy_pD9391rKyGmsL3sJQ-WbCTdK-kc5epcQj6J0uU-EeC8xgJBUcrEWvokLpmHmcUqBmwOoy3Ossml_DpLZ3upvjAmrJMH7gbuCPGF0xz3uVJaIHNAOIRWvsqzKrHtlXXOcrYlU4FqJbAvdf9hCiD1Rz-7VLN-xVHBn-eytwu1Yv33l-S9PakfL7m3AY2fkacBOdJh1-Ln5IGvX5DHo23Ctpfk9xg1funQzh0ta0e_-Y1tbjHAjk7KW0_PmzWGBsE31g0N0k10OryYxqPmKubx1fxms6LhiHAR7mdSc9c9wgsQ9TXFc1s6jU8Xd7ZpNR6AWLcCH8s5ANY4oYBD_RKIPMWVZuF_vSKX45Pvo0kcsi7EFrDUOgb-UXlljHWZ9lpWqZPSG-UzVBBNAe-k0jFuE2QaMmeO505yZ7hPNRNVZcRrclA3tX9LaOWUsFJYMHku4WPaC2t45kVu8kSrKiJsa4XCBklyzIyxKICaoOGKe4aLyJfdK8tOj-NvlY_RtLuKKKXdPgAHK4KDFf9ysIh8RscocMJD42wZ7i1AF1E6qxii_o9MmVQROezVBPPbfvHWtYqwUKwKrjQAKAHtj8jHXTG-icFvtW82bR0YfK4Ui8ibzhN3XRJZzvDoLiK656O9PvdL6vmPVkY8afG6FO_-xyi9J084wL8uOu-QHKxvNv4DwLW1GZCHaqbgV49PB-TR8cnZ-cWgna1_AMvjQUs
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELfGeBgviP8EBhgJhIQUzbGdOHlAqBS6jpUJ0W3aW5bYzqhUktKmg34Qvgafkbv8KYsm7W2vsWPZufPd75zz7wh5JRITWU-A8qYaAhSlUjeU1nMTZmFnsYxBNIfZFgfB8Eh-PvFPNsjf9i4MplW2NrEy1KbQeEa-w1UInkYIEb2f_XSxahT-XW1LaNRqsW9XvyBkW7zb-wjyfc354NNhf-g2VQVcDVihdAFfZ1alqTZBaEOZ-UZKmyobIEOmD_7cl4Zx7SGSlhEzPDKSm5RbP2Qiy1IB494gNyXEdriLwsHuOsDzwBvWf05hmmznR13g1i441g3gkez4vqpEwGVHcMETdrM0L7i9wR1yu8GrtFcr2F2yYfN7ZKvflom7T_4MkFmY9vTE0CQ3dGSXujjHtD46TM4t_VqUmJAEY5QFbQij6Lj3bez2i2OXu8eT-XJBm4PJaXMrlKar-hFeu8jPKJ4W07G7O13pomKWgHC-ohWZTQAmux4F9GtnZTGnaN-m9vcDcnQtUnlINvMit48JzYwSWgoNihZJGCy0Qqc8sCJKIy9UmUNYK4VYN0ToWI9jGkNAhIKLLwnOIW_Xr8xqFpCrOn9A0a47IoF39aCYn8WNPYgRNpuQI3xLpJZBBHG0CJXNoiDztPQc8gYVI0YzA5PTSXNbApaIhF1xD1mHpM-kcsh2pyeIX3ebW9WKG_O0iP9vJoe8XDfjm5hyl9tiWfWBj8-VYg55VGviekkiiBgeGDok7OhoZ83dlnzyvSIv96ooQYonV8_rBdkaHn4ZxaO9g_2n5BYHaFln_m2TzXK-tM8ACpbp82r_UXJ63Rv-H2npcyY
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELfGkIAXxH8CA4wEQkKKmthOHD8gVDq6jk3TRNm0tyyxnVGpJKVNB_0gfBk-HXf5UxZN2tteY8eyc-e73znn3xHyhidGWZ-D8qYaAhQpUzcS1ncTz8LO8jIPojnMtjgIR0fiy0lwskH-tndhMK2ytYmVoTaFxjPyHpMReBrOueplTVrE4fbw4-ynixWk8E9rW06jVpE9u_oF4dviw-42yPotY8PP3wYjt6kw4GrADaULWDuzMk21CSMbiSwwQthU2hDZMgPw7YEwHtM-omqhPMOUEcykzAaRx7Ms5TDuDXJTcqkwnTAa7qyDPR88Y_0XFabs9X7UxW7tgmENAaZExw9W5QIuO4ULXrGbsXnBBQ7vkbsNdqX9Wtnukw2bPyC3B23JuIfkzxBZhmlfTwxNckP37VIX55jiR0fJuaWHRYnJSTBGWdCGPIqO-1_H7qA4dpl7PJkvF7Q5pJw2N0Rpuqof4RWM_IziyTEduzvTlS4qlgkI7SuKkdkEILPrU0DCdlYWc4q2bmp_PyJH1yKVx2QzL3L7lNDMSK4F16B0SsBgkeU6ZaHlKlV-JDOHeK0UYt2QomNtjmkMwREKLr4kOIe8X78yqxlBrur8CUW77ohk3tWDYn4WN7YhRghtIoZQLhFahApiah5Jm6kw87XwHfIOFSNGkwOT00lzcwKWiORdcR8ZiETgCemQrU5PEL_uNreqFTemahH_31gOeb1uxjcx_S63xbLqAx-fSek55Emtiesl8VB5eHjokKijo501d1vyyfeKyNyvIgbBn109r1fkFmz1eH_3YO85ucMAZdZJgFtks5wv7QtAhWX6stp-lJxe937_B6RId1s
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Folic+Acid+and+Leucovorin+Have+Potential+to+Prevent+SARS-CoV-2-Virus+Internalization+by+Interacting+with+S-Glycoprotein%2FNeuropilin-1+Receptor+Complex&rft.jtitle=Molecules+%28Basel%2C+Switzerland%29&rft.au=%C5%A0krbi%C4%87%2C+Ranko&rft.au=Travar%2C+Maja&rft.au=Stojiljkovi%C4%87%2C+Milo%C5%A1+P&rft.au=Djuric%2C+Dragan+M&rft.date=2023-03-01&rft.issn=1420-3049&rft.eissn=1420-3049&rft.volume=28&rft.issue=5&rft_id=info:doi/10.3390%2Fmolecules28052294&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1420-3049&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1420-3049&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1420-3049&client=summon